Differential Effects of Mibefradil, Verapamil, and Amlodipine on Myocardial Function and Intracellular Ca\(^{2+}\) Handling in Rats with Chronic Myocardial Infarction

JIANG-YONG MIN, STEFFEN SANDMANN, ACHIM MEISSNER, THOMAS UNGER, and RUEDIGER SIMON

Department of Cardiology (J.-Y.M., A.M., R.S.), Institute of Pharmacology (S.S., T.U.), University of Kiel, Germany

Accepted for publication August 12, 1999 This paper is available online at http://www.jpet.org

ABSTRACT

Mibefradil is a selective T-type Ca\(^{2+}\) channel blocker that exerts a potent vasodilating but weak inotropic action. The present study compared mibefradil with traditional L-type Ca\(^{2+}\) channel blockers in regard to the effects of chronic oral administration on hemodynamics, contractility, and intracellular Ca\(^{2+}\) handling in failing myocardium from postinfarction rats. Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction. Six weeks after myocardial infarction, hemodynamic measurements were performed in conscious animals. In addition, isometric force and free [Ca\(^{2+}\)]\(_i\) were determined in isolated left ventricular papillary muscles. Placebo-treated rats exhibited a decreased mean atrial pressure, an increased left ventricular end-diastic pressure, and a reduced rate of pressure rise compared with sham-operated animals. Mibefradil treatment significantly improved all of these parameters, whereas both amlodipine and verapamil exerted only minor effects. \(\beta\)-Adrenergic stimulation with isoproterenol (ISO) enhanced contractility and Ca\(^{2+}\) availability in papillary muscles from sham-operated rats, whereas the ISO-induced inotropic effect in muscles from placebo-treated rats was severely blunted. Chronic mibefradil treatment significantly improved the inotropic response to ISO stimulation, although the Ca\(^{2+}\) availability appeared to be less than in muscles from placebo-treated animals. In contrast, both verapamil and amlodipine did not restore the inotropic and Ca\(^{2+}\) availability-modulating effect of ISO in remodeled myocardium. Thus, T-type Ca\(^{2+}\) current appears to be of pathophysiological relevance in postischemic reperfused myocardium.

Calcium channel blockers (CCBs) have been extensively used in the treatment of cardiovascular disease (Braunwald, 1982; Held et al., 1989). However, recent clinical studies raised concerns about their potential negative effects on morbidity and mortality in patients with coronary artery disease and hypertension (Yusuf, 1995). In particular, the use of CCBs in chronic myocardial infarction (MI) did not improve or even deteriorate the odds of adverse clinical outcomes (Held et al., 1989; Diltiazem Postinfarction Trial Group, 1989). The conventional CCBs are subdivided into three major chemical classes (dihydropyridines, phenylalkylamines, and benzothiazepines) but share a common mechanism of action, i.e., selective inhibition of the transmembrane flux of calcium into the cell via L-type (long-lasting, high voltage-activated) Ca\(^{2+}\) channels (Opie et al., 1987). The resulting vasodilation and negative inotropy potentially induce a reflex increase in sympathetic tone that may negatively affect prognosis (Noll et al., 1988).

Mibefradil is a member from a new chemical class of CCBs (benzimidazolyl-substituted tetraline derivative) that is \(\sim\)30 to 100 times more potent in blocking T-type (transient, low voltage-activated) than L-type Ca\(^{2+}\) channels in vascular smooth muscle (Mishra and Hermsmeyer, 1994). Conversely, CCBs of the dihydropyridine, phenylalkylamine, and benzothiazepine classes have no ability to block T-type calcium channels at therapeutic concentrations (Triggle, 1991). T-type Ca\(^{2+}\) channels are mainly present in smooth muscle and sinus node cells but also are found in rapidly proliferating cells as well as hypertrophied cardiac myocytes (Hagiwara et al., 1988; Nuss and Houser, 1993; Schmitt et al., 1995; Katz, 1996).

The in vivo effects of mibefradil include potent peripheral vasodilation, coronary vasodilation, and a decrease in heart rate (Luescher et al., 1997). At therapeutic concentrations, the drug exerts no negative inotropic action and does not stimulate the sympa-tho-adrenergic reflex activity (Schmitt et al., 1992; Su et al., 1994). Inhibition of vascular smooth muscle and mesangial cell proliferation by mibefradil posi..
tively affects vascular remodeling in hypertension (Hermeyer and Miyagawa, 1996). Similarly, mibefradil has been demonstrated to induce beneficial effects on the cardiac remodeling process after acute myocardial infarction in rats (Mulder et al., 1997; Sandmann et al., 1998).

Contractile dysfunction in failing myocardium has been attributed to alterations of the intracellular Ca\(^{2+}\) homeostasis (Morgan et al., 1990). T-type Ca\(^{2+}\) current is negligible in normal adult ventricular but is re-expressed by the reactivated fetal gene program in remodeled and hypertrophied ventricular myocytes (Nuss and Houser, 1993; Qin et al., 1995). The pathophysiological relevance of this phenomenon is unknown but might be related to arrhythmias and mechanical impairment in postinfarction myocardium. Therefore, the purpose of this study was to investigate the hemodynamic, inotropic, and [Ca\(^{2+}\)]\(_\text{cyt}\)modulating effects of chronic mibefradil treatment in the infarcted rat heart and to perform a comparison with L-type CCBs exhibiting a prominent cardiac (verapamil) or vascular (amlodipine) site of action at therapeutic concentrations.

**Materials and Methods**

The experiments were performed in male Wistar rats (Charles River Viga, Sulzfeld, Germany) with an initial body weight of 250 to 300 g. The animals were housed individually under climate-controlled conditions with a 12-h light/dark cycle and provided with standardized rat chow and tap water ad libitum. The investigation conformed with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication 85-23, revised 1985).

**Animal Model of MI.** MI was induced by left anterior descending coronary artery ligation according to a previously described technique (Pfeffer et al., 1985). Endotracheal intubation was performed and followed by artificial ventilation during anesthesia with ether. Subsequently, anesthesia was maintained with i.v. methohexitol sodium given via the tail vein. The chest was opened by a left-sided sternal incision. A rib-spreading chest retractor was inserted and the left anterior descending coronary artery was ligated byatraumatic suture with 6.0 sterile silk. The successful ligation of the coronary artery was verified by surface ECG recording and visual change of color in the infarcted area. The thoracic cavity was closed by interrupted sutures. The sham-operated rats underwent an identical surgical procedure without coronary ligation.

**Drug Randomization.** Previous studies demonstrate that the protective effects of L-type Ca\(^{2+}\) channel blockers on ischemic, reperfused, and postischemic myocardium become most evident if the drug regimen starts before the induction of ischemia (Nayler et al., 1978; Klein et al., 1984; Lo et al., 1985). Therefore, the study protocol used a similar approach to maximize beneficial effects and allow for comparisons between a reasonable number of animals in each treatment group. The rats were treated with mibefradil (10 mg/kg/day; Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany), verapamil (8 mg/kg/day; Sigma-Aldrich GmbH, Deisenhofen, Germany), amlodipine (4 mg/kg/day; Pfizer GmbH, Karlsruhe, Germany), or placebo by oral gavage once daily starting 7 days before induction of MI. In a previous set of experiments, these dosages had been tested and shown to not significantly alter the mean arterial blood pressure in infarcted or sham-operated animals. This regimen was continued in the surviving animals until sacrifice at 6 weeks post-MI. A total of seven or eight rats was operated on in each group. The peri-infarct mortality (1 or 2 rats in each group) was similar in all groups so that the study cohort comprised a total of 30 surviving rats with 6 animals in each of the following groups: untreated sham-operated rats (sham group), placebo-treated rats with coronary ligation (placebo-MI group), mibefradil-treated rats with coronary ligation (mibefradil-MI group), verapamil-treated rats with coronary ligation (verapamil-MI group), and amlodipine-treated rats with coronary ligation (amlodipine-MI group).

**Hemodynamic Measurements.** Six weeks after MI or sham operation, chronic arterial and venous catheters, as well as a catheter in the left ventricle, were implanted to measure hemodynamic data. Anesthesia was initiated with diethylether and continued by i.v. methohexitol-sodium (10 mg/kg). Femoral arterial and venous catheters were chronically implanted with a procedure described previously (Unger et al., 1984). In short, polypropylene tubes (Portex, London, UK) were inserted into the right femoral artery and vein and exteriorized at the nape of the neck. The right carotid artery was cannulated with a specially constructed pig-tail catheter (Stauss et al., 1988) that was retrogradely passed across the aortic valve and advanced into the left ventricle. The distal portion of the catheter was then tunneled under the skin and anchored at the posterior neck region. The hemodynamic studies were performed 24 h later in conscious animals with conventional pressure transducers (DTX/Plus; Spectramed Inc, Oxnard, CA) and processors (Gould Inc., Cleveland, OH). Mean arterial blood pressure (MAP), heart rate, left ventricular end-diastolic pressure (LVEDP), and maximum positive change of left ventricular pressure (dP/dtmax) were documented on a pen recorder (Gould Series 2000; Gould Inc.) and processed with a computer-based analyzing system as described previously (Stauss et al., 1990).

**Isometric Muscle Performance.** Immediately after completion of the hemodynamic measurements, the rats were sacrificed during deep anaesthesia with ether. The heart was rapidly excised and placed in a dissecting chamber containing a modified Krebs-Henseleit solution of the following composition: 120 mM NaCl, 5.9 mM KCl, 5.5 mM dextrose, 2.5 mM NaHCO\(_3\), 12 mM NaH\(_2\)PO\(_4\), 1.2 mM MgCl\(_2\), 1.0 mM CaCl\(_2\), pH 7.4, bubbled with carbogen (a mixture of 95% O\(_2\) and 5% CO\(_2\)) at room temperature. The noninfarcted left ventricular papillary muscle was carefully dissected and then fixed to a muscle holder with a spring clip. The tendinous end of the muscle was vertically connected to a strain-gauge platinum electrode with square-wave pulses of 5-ms duration at 0.33 Hz. The voltage was set to 10% above threshold level. After a 30-min equilibration period, the muscle was carefully stretched to the length at which maximal tension occurred (Lmax). The following isometric contraction parameters were recorded from each muscle at this maximal length: developed tension (TDT, tension produced by the stimulated muscle), time to peak tension (time from the beginning of the contraction to peak tension), and time to 50% relaxation (time from peak tension to 50% of relaxation). Subsequently, the loading procedure for aequorin was performed (see below). At the end of the experiment, the muscle was blotted and weighed. The cross-sectional area was determined from muscle weight and length by assuming a uniform cross-section and a specific gravity of 1.05. After removal of the papillary muscle for study, the weights of the right and left ventricle, including the septum, were normalized by body weight and used as indices of hypertrophy.

**Aequorin Light Signal Measurement.** Aequorin (courtesy of Dr. John Blinks, Friday Harbor Laboratories, Friday Harbor, WA) was loaded into the nonstimulated muscle preparation by microinjection technique (Meissner et al., 1994). Briefly, the preparation was raised into a voltage signal. Analog signals from the isometric force trans-

---

**Differential Effects of Ca\(^{2+}\) Channel Blockers in Chronic Myocardial Infarction**

---

**1039**
ducer and electronic photometer were recorded with a chart-strip recorder (Model 56-1X 40-006158; Gould Inc.) and stored on videotape (Model HR-J40U; JVC Company of America, Elmwood Park, NJ). To improve the signal-to-noise ratio, 8 to 64 steady-state light signals and isometric twitches were averaged with a digital oscilloscope (model 5460113, 100 MHz; Hewlett-Packard GmbH, Böblingen, Germany) for quantitative measurements.

Parameters derived from the light signals included the amplitude of the light transient, time to peak light, and time from peak to 50% fall in peak light (RI50). The free [Ca2+]i, was estimated by normalizing the recorded light signal during isometric twitches (L) by the maximal amount of light emitted after lysis of the muscle membranes (Lmax) at the end of experiment with a 5% solution of the detergent Triton X-100 in phosphate-free physiological salt solution containing 50 mM Ca2+. The normalized light signal was then converted to [Ca2+]i, with an in vitro calibration curve as previously reported (Meissner et al., 1996).

**Isoproterenol (ISO) Dose-Response Determinations.** After baseline parameters were obtained, ISO (10−7, 10−6, 10−5, 10−4 M; Sigma-Aldrich GmbH, Deisenhofen, Germany) was added cumulatively to determine the inotropic response to β-adrenergic stimulation. Light signals and isometric contractions were measured 10 min after each dose of ISO.

**Statistical Analysis.** All values are given as means ± S.E. Data were evaluated by one-way ANOVA with repeated measures. Differences between individual groups were compared by using Student’s t test and considered significant at p < .05.

**Results**

**Morphology and Hemodynamics.** Six weeks after infarction, the left ventricular weight and left ventricular weight-to-body weight ratio in placebo-treated rats were significantly increased compared with sham-operated animals (Table 1). Chronic treatment with CCBs decreased left ventricular hypertrophy to a similar degree in all groups. Animals in the placebo-MI group exhibited a smaller rate of pressure rise (dP/dtmax), a lower MAP, and a LVEDP than sham-operated animals (Table 3). In the mibeferadil-MI group, DT appeared to be almost completely preserved, whereas it was significantly decreased in both the verapamil-MI and amlodipine-MI group. The time course of contraction was prolonged to a similar extent in all drug-treated groups.

**β-Adrenergic stimulation with cumulative concentrations of ISO induced a pronounced increase in DT in normal papillary muscles from sham-operated animals (Table 3). In the mibeferadil-MI group, DT appeared to be almost completely preserved, whereas it was significantly decreased in both the verapamil-MI and amlodipine-MI group. The time course of contraction was prolonged to a similar extent in all drug-treated groups.**

**Systolic [Ca2+]i Measurements.** At baseline, the peak systolic [Ca2+]i, in isolated noninfarcted papillary muscles of the placebo-MI group and in papillary muscles of the sham-operated group were equivalent (Table 3). In the mibeferadil-MI group, systolic [Ca2+]i, was found at a similar level, whereas it was significantly reduced in both the verapamil-MI and amlodipine-MI group. The time course of the Ca2+ transient exhibited a significant prolongation in the placebo-MI, verapamil-MI, and amlodipine-MI groups but only a minor change in the mibeferadil-MI group (Fig. 4).

**Cumulative ISO-stimulation increased peak systolic [Ca2+]i, in parallel to DT in papillary muscles from sham-operated rats; placebo-MI, infarcted rats at 6 weeks post-MI with placebo treatment; mibeferadil-MI, infarcted rats at 6 weeks post-MI with mibeferadil treatment; verapamil-MI, infarcted rats at 6 weeks post-MI with verapamil treatment; amlodipine-MI, infarcted rats at 6 weeks post-MI with amlodipine treatment (n = 6 in each group).**

**TABLE 2**

<table>
<thead>
<tr>
<th>HR</th>
<th>MAP</th>
<th>LVEDP</th>
<th>dP/dtmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>361 ± 5.6</td>
<td>111 ± 2.1</td>
<td>10.2 ± 1.1</td>
</tr>
</tbody>
</table>
| Placebo-MI | 373 ± 6.2 | 82 ± 2.0 | 21.1 ± 2.3 | 4.9 ± 0.5
| Mibeferadil-MI | 369 ± 5.4 | 102 ± 2.4 | 14.1 ± 2.7 | 7.1 ± 0.4
| Verapamil-MI | 343 ± 4.6 | 81 ± 2.2 | 20.0 ± 2.6 | 5.3 ± 0.6
| Amlodipine-MI | 372 ± 5.1 | 96 ± 2.3 | 18.1 ± 2.4 | 5.9 ± 0.5 |

| Values are means ± S.E. |

**TABLE 1**

<table>
<thead>
<tr>
<th>General characteristics of sham-operated and MI rats</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td>Sham</td>
</tr>
<tr>
<td>Placebo-MI</td>
</tr>
<tr>
<td>Mibeferadil-MI</td>
</tr>
<tr>
<td>Verapamil-MI</td>
</tr>
<tr>
<td>Amlodipine-MI</td>
</tr>
</tbody>
</table>

BW, body weight; LVW, left ventricular weight; RVW, right ventricular weight; LVW/BW, ratio of left ventricular weight/body weight; RVW/BW, ratio of right ventricular weight/body weight; CSA, papillary muscle cross-sectional area; sham, papillary muscles from sham-operated rats; placebo-MI, papillary muscles from MI rats with placebo treatment at 6 weeks post-MI; mibeferadil-MI, papillary muscles from MI rats with mibeferadil treatment at 6 weeks post-MI; verapamil-MI, papillary muscles from MI rats with verapamil treatment at 6 weeks post-MI; amlodipine-MI, papillary muscles from MI rats with amlodipine treatment at 6 weeks post-MI.

*p < .05 versus sham, mibeferadil-MI, verapamil-MI, and amlodipine-MI group.
TABLE 3
Parameters of mechanical contractility and free intracellular Ca^{2+} concentration in isolated papillary muscles from sham-operated and MI rats with placebo or drug administration

<table>
<thead>
<tr>
<th></th>
<th>DT (ms)</th>
<th>TPT (mN/mm²)</th>
<th>RT_{50} (ms)</th>
<th>TPL (ms)</th>
<th>RL_{50} (ms)</th>
<th>Systolic [Ca^{2+}]_i (μM)</th>
<th>Diastolic [Ca^{2+}]_i (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>12.8 ± 0.15</td>
<td>87.3 ± 8.4</td>
<td>55.3 ± 4.5</td>
<td>38.2 ± 2.8</td>
<td>44.8 ± 4.1</td>
<td>0.61 ± 0.07</td>
<td>0.28 ± 0.03</td>
</tr>
<tr>
<td>Placebo-MI</td>
<td>11.7 ± 0.19</td>
<td>103.4 ± 9.5*</td>
<td>59.5 ± 5.2*</td>
<td>45.7 ± 4.2**</td>
<td>51.2 ± 4.4**</td>
<td>0.69 ± 0.09</td>
<td>0.35 ± 0.05**</td>
</tr>
<tr>
<td>Mibefradil-MI</td>
<td>12.3 ± 0.16</td>
<td>101.5 ± 8.7*</td>
<td>57.2 ± 4.8</td>
<td>41.3 ± 2.7*</td>
<td>45.3 ± 3.6</td>
<td>0.57 ± 0.04</td>
<td>0.29 ± 0.05</td>
</tr>
<tr>
<td>Verapamil-MI</td>
<td>7.3 ± 0.14**</td>
<td>106.4 ± 9.8*</td>
<td>61.5 ± 6.1*</td>
<td>43.2 ± 3.1*</td>
<td>50.3 ± 2.5*</td>
<td>0.51 ± 0.02*</td>
<td>0.34 ± 0.02*</td>
</tr>
<tr>
<td>Amlodipine-MI</td>
<td>8.4 ± 0.20**</td>
<td>105.2 ± 9.6*</td>
<td>60.1 ± 5.2*</td>
<td>42.6 ± 2.3*</td>
<td>49.6 ± 2.8*</td>
<td>0.52 ± 0.03*</td>
<td>0.33 ± 0.02*</td>
</tr>
</tbody>
</table>

TPT, time to peak tension; RT_{50}, time from peak tension to 50% relaxation; TPL, time to peak light signal; RL_{50}, time from peak light to 50% decline; Systolic [Ca^{2+}]_i, peak systolic free [Ca^{2+}]_i concentration; Diastolic [Ca^{2+}]_i, diastolic free [Ca^{2+}]_i concentration; sham, papillary muscles from sham-operated rats; placebo-MI, papillary muscles from MI rats with placebo treatment at 6 weeks post-MI; mibefradil-MI, papillary muscles from MI rats with mibefradil treatment at 6 weeks post-MI; verapamil-MI, papillary muscles from MI rats with verapamil treatment at 6 weeks post-MI; amlodipine-MI, papillary muscles from MI rats with amlodipine treatment at 6 weeks post-MI.

*p < .05 versus sham group.
**p < .01 versus sham group.
#p < .05 versus mibefradil-MI group.

Discussion

Postinfarction myocardial remodeling is a complex transformation of left ventricular morphology and function involving both infarcted and noninfarcted areas. This process includes dilatation and thinning of the infarcted left ventricular wall segments as well as a compensatory reactive hypertrophy of the remaining viable myocardium (Pfeffer and Braunwald, 1990). Experimental studies suggest that L-type Ca^{2+} channel blockers may provide protective effects in the ischemic and reperfused heart by way of a modulation of the myocardial Ca^{2+} homeostasis (Nayler et al., 1980; Amende et al., 1992). Moreover, intracellular Ca^{2+} homeostasis seems to play a permissive or potentiating role in activating several second messenger systems involved in the regulation of myocardial growth and hypertrophy (Sadoshima and Izumo, 1993). In contrast, the results of clinical trials with L-type CCBs in patients with myocardial infarction have been negative and do not support a therapeutic concept based upon intracellular Ca^{2+} modulation.

The present study demonstrates that chronic treatment with verapamil, amlodipine, and mibefradil reduced compensatory left ventricular hypertrophy to a similar degree in the postinfarction rat model. This finding may reflect a beneficial effect on the myocardial remodeling process resulting from an initial reduction of infarct size (Weishaar and Bing, 1980; Sandmann et al., 1998). Surprisingly, this common morphological feature in the drug-treated animals was not associated with equally uniform changes of the hemodynamic situation. Chronic treatment with verapamil and amlodipine had no or only minor effects on LVEDP, MAP, and dP/dtmax.
compared with those of placebo-treated animals. In contrast, mibefradil significantly reduced preload (LVEDP), improved contractility (dP/dtmax), and increased MAP in chronically infarcted rats, confirming the results of a previous study (Sandmann et al., 1998). Thus, T-type Ca$^{2+}$ channel blockade with mibefradil induces an improvement of myocardial function that cannot solely be attributed to its effects on left ventricular hypertrophy but might be related to changes of the intracellular Ca$^{2+}$ homeostasis. Myocardium from rats with postinfarction heart failure has been shown to exhibit a severely blunted inotropic response to $\beta$-adrenergic stimulation despite a large increase in the amplitude of the Ca$^{2+}$, transient (Litwin and Morgan, 1992). The present study shows that chronic treatment with verapamil or amlodipine resulted in a further deterioration of isometric force as well as a reduction of the systolic Ca$^{2+}$, availability during ISO stimulation. In contrast, chronic treatment with mibefradil partially restored the $\beta$-adrenergic, inotropic responsiveness in remodeled myocardium from postinfarction rats although the systolic [Ca$^{2+}$], remained depressed. It is tempting to speculate that this phenomenon is due to either an increased Ca$^{2+}$ responsiveness of the myofilaments or a modification of the diastolic Ca$^{2+}$ homeostasis or, mutually related, both. Elevation of [Ca$^{2+}$], induces changes in protein synthesis and degradation as well as activation of phosphorylating and proteolytic enzymes that affect the contractile proteins (Kusuoka et al., 1990; Sadoshima et al., 1995). Lowering of diastolic [Ca$^{2+}$], by chronic mibefradil treatment may have ameliorated these perturbations resulting in a preserved myofibrillar Ca$^{2+}$ responsiveness.

Abnormal intracellular Ca$^{2+}$ handling has been suggested as a major source of contractile dysfunction in failing myocardium (Morgan et al., 1990). In particular, elevation of the diastolic [Ca$^{2+}$], may generate temporal and spatial inhomogeneities of [Ca$^{2+}$] which, in turn, increase diastolic tone, reduce systolic force generation, and trigger arrhythmias (Lakatta, 1989). In fact, chronic treatment with mibefradil significantly reduced diastolic [Ca$^{2+}$], in remodeled myocardium from postinfarction rats compared with placebo-, verapamil-, or amlodipine-treated animals. Moreover, ISO-stimulation induced diastolic Ca$^{2+}$ oscillations in all papillary muscles from the placebo-, verapamil-, and amlodipine-MI group, whereas no such phenomena could be elicited in preparations from the mibefradil-MI or sham-operated group.

Experimental studies suggest that exposure to ISO induces an increase in T-type Ca$^{2+}$ current secondary to a rise in [Ca$^{2+}$], after augmentation of the L-type Ca$^{2+}$ current (Tseng and Boyd, 1991). The threshold for opening of the T-type Ca$^{2+}$ channel is lower than that of the L-type Ca$^{2+}$ channel and a slight deviation from the resting potential may gener-
Differential Effects of Ca²⁺ Channel Blockers in Chronic Myocardial Infarction

Fig. 3. Aequorin light signal and isometric contraction from representative rat papillary muscles of MI groups with mibefradil (A), verapamil (B), or amiodipine (C) treatment during ISO stimulation. Upper trace, isometric contraction; lower trace, light signal. Diastolic Ca²⁺ oscillations and mechanical aftercontractions are marked by arrows.

Fig. 4. Time intervals of the intracellular light transient at baseline and during ISO stimulation (10⁻⁴ M) in papillary muscles from sham-operated and myocardial infarction rats. Sham, sham-operated group; placebo-MI, MI group with placebo treatment; mibefradil-MI, MI group with mibefradil treatment; verapamil-MI, MI group with verapamil treatment; amiodipine-MI, MI group with amiodipine treatment (n = 6 in each group). TPL, time to peak light; RL₅₀, time from peak light to 50% decline. *p < .05, **p < .01 versus sham-operated group; #p < .05 versus mibefradil-MI group.

References


Send reprint requests to: Achim Meissner, M.D., Department of Cardiology, University of Kiel, Schittenhelmstrasse 12, D-24105 Kiel, Germany. E-mail: meissner@cardio.uni-kiel.de